Trial
NCT02319369
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Acute Myelogenous Leukemia
Intervention
Milademetan
Why stopped
This study was terminated based on a business decision by the Sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-11